SCHEMBL4777523

SCHEMBL4777523

FC(F)(F)C(F)(F)COc1ccc(NC2CCNCC2)cc1

nearest known ligand 0.42

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
EPHX1 P07099 1/20 0.42
CTSL P07711 2/20 0.41
CTSB P07858 2/20 0.41
CTSS P25774 2/20 0.41
CTSK P43235 2/20 0.41
FLT3 P36888 1/20 0.40
MAPK1 P28482 1/20 0.40
MAPT P10636 1/20 0.38
HTR6 P50406 5/20 0.37
CHEK1 O14757 1/20 0.36
CACNA1B Q00975 1/20 0.36
KDM1A O60341 2/20 0.36
RCOR1 Q9UKL0 1/20 0.36
TDP1 Q9NUW8 1/20 0.35
MAOA P21397 2/20 0.35
MAOB P27338 2/20 0.35
PLK4 O00444 1/20 0.34
MMP13 P45452 1/20 0.34
MMP14 P50281 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5536264 0.78 EPHX1 (0.64) EPHX1CTSLCTSBCTSSCTSK
Hydrochloric Acid SCHEMBL76279 0.77 HRH1 (0.50) TDP1MMP13MMP14
Hydrochloric Acid SCHEMBL411544 0.77 EPHX1 (0.63) EPHX1CTSLCTSBCTSSCTSK
SCHEMBL7042985 0.73 MAOB (0.62) CACNA1BKDM1AMAOAMAOB
SCHEMBL2233187 0.73 MAOB (0.43) CTSLCTSBCTSSCTSKHTR6
SCHEMBL1704613 0.72 HTR6 (0.57) MAPK1HTR6CACNA1B
SCHEMBL4140224 0.72 HTR6 (0.57) CTSLCTSBCTSSCTSKMAPK1
Hydrochloric Acid SCHEMBL23303031 0.71 HTR6 (0.58) MAPK1HTR6CACNA1B
SCHEMBL377433 0.70 HTR6 (0.54) CTSLCTSBCTSSCTSKMAPK1
SCHEMBL7695976 0.69 MAPT (0.43) EPHX1MAPTHTR6CHEK1KDM1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7348324-B2 Cyclic amine compounds as CCR5 antagonists TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2008-03-25 US disclosed
EP-1886994-A1 Cyclic amine compounds as CCR5 antagonists Takeda Pharmaceutical Company Limited (JP) 2008-02-13 EP disclosed
US-20030114443-A1 Cyclic amine compounds as CCR5 antagonists TOBIRA THERAPEUTICS, INC. 2003-06-19 US disclosed
EP-1220842-A1 CYCLIC AMINE COMPOUNDS AS CCR5 ANTAGONISTS Takeda Chemical Industries, Ltd. (JP) 2002-07-10 EP disclosed
WO-2001025200-A1 CYCLIC AMINE COMPOUNDS AS CCR5 ANTAGONISTS TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) 2001-04-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030114443-A1 Cyclic amine compounds as CCR5 antagonists CCR5, CCR1, CCR3 EPHX1 1547/4885CTSL 3171/4885CTSB 4158/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.